User Experience of a Gait Training Treadmill for Home Rehabilitation of Children With Chronic Conditions

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age8-18
SponsorUniversity Hospital, Angers

About this trial

"In the context of limited accessibility to prolonged and efficient rehabilitation programs based on physical activity, this study aims to develop a home program for children with chronic diseases affecting physical health (including cerebral palsy, obesity, and neuromuscular diseases). The French company EzyGain has designed a compact treadmill equipped with sensors and a safety system, which communicates with a tablet application and a virtual reality headset to support at-home rehabilitation. This study seeks to advance the development of this solution into a prolonged and progressive training program, tailored to positively impact children's health. Future users, including children, their parents, and therapists, will be at the heart of the development process. A qualitative methodology will be employed, incorporating focus groups and a series of user experience (UX) questionnaires. The research hypothesis is that user feedbacks will enable the development of an appropriate solution that meets their specific needs and ensures high adoption rates of the device.

This study is the first step before assessing the impact of the solution in these 3 groups of children (with cerebral palsy, obesity and neuromuscular disease)."

Eligibility criteria

Qualifiers

aged between 8 and 18 years old

capable of walking during 5 minutes on a treadmill with or without walking aid, and with or without body weight support

diagnosis of one the following pathology: bilateral cerebral palsy, obesity, spinal muscular amiotrophy type 3, Duchenne, congenital myopathy, Charcot Marie Tooth

Gross Motor Function Classification System (GMFCS) I to III for the children with cerebral palsy

Disqualifiers

Deprived of liberty by judicial or administrative decision

Subject to a legal protection measure"

Trial design

Treatments tested in this trial

  • No intervention

Treatment groups

75 Participants
are divided into 1 treatment group

Sponsors and collaborators